AI-based digital pathology provides newer insights into lifestyle intervention-induced fibrosis regression in MASLD: An exploratory study.

Journal: Liver international : official journal of the International Association for the Study of the Liver
PMID: 38963299

Abstract

BACKGROUND AND AIMS: Lifestyle intervention is the mainstay of therapy for metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis is a key consequence of MASH that predicts adverse clinical outcomes. The placebo response plays a pivotal role in the outcome of MASH clinical trials. Second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy with artificial intelligence analyses can provide an automated quantitative assessment of fibrosis features on a continuous scale called qFibrosis. In this exploratory study, we used this approach to gain insight into the effect of lifestyle intervention-induced fibrosis changes in MASH.

Authors

  • Hai-Yang Yuan
    MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Xiao-Fei Tong
    Liver Research Center, Beijing Friendship Hospital, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Capital Medical University, Beijing, China.
  • Ya-Yun Ren
    HistoIndex Pte Ltd, Singapore.
  • Yang-Yang Li
    Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Xin-Lei Wang
    HistoIndex Pte Ltd, Singapore.
  • Li-Li Chen
    Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, Province Guangdong, People's Republic of China.
  • Sui-Dan Chen
    Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Xiao-Zhi Jin
    MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Xiao-Dong Wang
    Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China.
  • Giovanni Targher
    Department of Medicine, University of Verona, Verona, Italy.
  • Christopher D Byrne
    Southampton National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton General Hospital, Southampton, UK.
  • Lai Wei
  • Vincent W-S Wong
    Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
  • Dean Tai
    HistoIndex Pte Ltd, Singapore.
  • Arun J Sanyal
    Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
  • Hong You
    Liver Research Center, Beijing Friendship Hospital, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Capital Medical University, Beijing, China.
  • Ming-Hua Zheng
    MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Keywords

External Resources

Popular Topics
Recent Journals